Gedea Biotech AB’s Post

Gedea Biotech is developing a treatment for vaginal infections that actually works, meaning an effective, antibiotic free and safe treatment for vaginal infections that treats the infection and minimizes the risk of recurrence. Meet one of our colleagues, Sten Kornfält, Clinical Project Manager What is your role at Gedea? I have been with Gedea for five years now and I’m responsible for our clinical investigations. Together with the team at Gedea I plan and design the investigations, and when the clinical projects are ongoing, I also manage them together with our CRO (Clinical Research Orgionization). When the studies are completed, I’m involved in the evaluation of the results.   What previous positions have you had? I have long experience working with clinical trials at different CROs, both as a Clinical Research Associate and as Project Manager.   What makes your job particularly meaningful? BV and VVC are huge burdens for many women and our product will make a difference for them. The product is safe and helps the microbiome to restore in a natural way. To help document this product and make it available on the market feels very meaningful.   Is there anything that is frustrating and testing your patience in your work? Clinical investigations take a long time to complete, and there are a lot of hurdles. Solving the problems is however also stimulating.   What is the next milestone or achievement in your work at Gedea? Gedea Biotech has a comprehensive and ambitious clinical program. It is important for us that the advantages of our product are thoroughly documented. We also want to understand what is happening in the vaginal microbiome in women that have BV or VVC, and how our product may positively alter the conditions that have caused the infections. The next milestone will be the completion of NEFERTITI-2 study in bacterial vaginosis.